Abate As Industries Ltd
Incorporated in 1991, Abate As Industries
Ltd primarily operates in the eye healthcare segment through its super specialty hospitals
and optical outlets[1]
- Market Cap ₹ 186 Cr.
- Current Price ₹ 11.8
- High / Low ₹ 26.2 / 9.62
- Stock P/E 17.6
- Book Value ₹ 10.8
- Dividend Yield 0.00 %
- ROCE %
- ROE 0.67 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.10 times its book value
Cons
- Promoter holding is low: 27.6%
- Company has high debtors of 430 days.
- Promoter holding has decreased over last 3 years: -4.31%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | TTM | |
|---|---|---|
| 14 | 140 | |
| 13 | 129 | |
| Operating Profit | 1 | 11 |
| OPM % | 5% | 8% |
| 1 | 3 | |
| Interest | 0 | 0 |
| Depreciation | 1 | 2 |
| Profit before tax | 1 | 11 |
| Tax % | -2% | |
| 1 | 11 | |
| EPS in Rs | 0.07 | 0.67 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 53% |
| 3 Years: | 14% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Sep 2025 | |
|---|---|---|
| Equity Capital | 79 | 158 |
| Reserves | 85 | 12 |
| 11 | 9 | |
| 31 | 36 | |
| Total Liabilities | 206 | 215 |
| 149 | 151 | |
| CWIP | 0 | 0 |
| Investments | 14 | 14 |
| 43 | 50 | |
| Total Assets | 206 | 215 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| -1 | |
| -162 | |
| 165 | |
| Net Cash Flow | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | 430 |
| Inventory Days | 413 |
| Days Payable | 209 |
| Cash Conversion Cycle | 635 |
| Working Capital Days | 640 |
| ROCE % |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations (Trading/Consultancy Phase) INR ・Standalone data |
|
|||||||||||
| Contract Asset Receivables (representing active service engagements) INR in '000s |
||||||||||||
| Experience in Retail/Wholesale (Sky International Subsidiary) Years |
||||||||||||
| Number of Fully Functional Eye Hospitals Number |
||||||||||||
| Number of Optical LLPs/Distribution Points Number |
||||||||||||
| Strategic Target for International Eye Hospitals Number |
||||||||||||
| Students Educated (BSc Optometry Program cumulative since 2005) Number |
||||||||||||
| Trade Receivables Turnover Times |
||||||||||||
Documents
Announcements
-
Intimation Under Regulation 7(2) Of The SEBI (PIT) Regulations, 2015 As Received From Al Salama Eye Research Foundation
2h - Reg 7(2) insider trading disclosure dated 10.03.2026 by Al Salama Eye Research Foundation (Promoter Group) for scrip 531658.
-
Intimation Of Disclosure Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015
2 Mar - Al Salama Eye Research Foundation bought 82,202 shares, raising holding to 1,361,334 (0.86%) on 26-27 Feb 2026.
-
Announcement Under Regulation 30- Launch Of Abate'S Indigenous EMR & Integrated Eye Hospital Clinic Management System
17 Feb - Abate launches indigenous EMR Integrated Eye Hospital Clinic Management System via Prudential Management Services.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Submission of newspaper advertisement published regarding unaudited financial results for the quarter ended 31.12.2025
-
Board Meeting Outcome for Submission Of Outcome Of Board Meeting Held On 12Th February 2026
12 Feb - Board approved Q3 unaudited results; authorized capital increased to Rs 3,200 crore; appointed Harikumar V as independent director.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
AAIL is a multi-sector enterprise with a diverse portfolio in healthcare, education, retail, technology, real estate, and consultancy
services.